Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2021-05-09 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Phase III Prostate Cancer Therapy Clinical Trial Commences 2 pages 218.3KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing the commencement of a Phase III clinical trial for a prostate cancer therapy by Telix Pharmaceuticals. It contains no financial data, regulatory filings, or detailed financial reports. It is not an annual or interim report, earnings release, or any form of financial statement. It is also not a regulatory filing, board or management change announcement, or any other specific filing type related to corporate governance or capital structure. The content is primarily a corporate announcement about clinical trial progress, which does not fit into the defined categories for financial or regulatory filings. Given the absence of financial or regulatory content, the best fit is Regulatory Filings (RNS) as a general announcement category for miscellaneous filings that do not fit other categories.
2021-05-09 English
Telix Appoints Mr Richard Valeix as EMEA President 2 pages 203.2KB
Board/Management Information Classification · 100% confidence The document is a company announcement about the appointment of a new executive, Mr. Richard Valeix, as EMEA President at Telix Pharmaceuticals. It details his background, experience, and the company's strategic direction. There is no financial data, no discussion of financial results, no regulatory filings, no voting results, no legal proceedings, and no mention of any report publication. The content focuses solely on management changes at the executive level. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 4906 characters, which is consistent with a typical management announcement. Confidence is high as the content clearly matches the MANG category.
2021-05-02 English
Executive Leadership Appointments and Establishment of APAC 2 pages 204.5KB
Board/Management Information Classification · 100% confidence The document is an announcement from Telix Pharmaceuticals Limited regarding executive leadership appointments and the establishment of a new operating region. It details changes in senior management roles and organizational structure. There is no financial data, no discussion of financial results, no regulatory filings of financial reports, no voting results, no legal proceedings, and no mention of capital or financing activities. The content focuses solely on management changes and organizational updates. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 5382 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report types.
2021-05-02 English
Manufacturing Agreement with Global Medical Solutions 2 pages 207.0KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of a strategic manufacturing agreement between Telix Pharmaceuticals Limited and Global Medical Solutions. It discusses the terms of the agreement, the products involved, and provides background information about both companies. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings data, and no detailed financial or operational report. The document is an announcement of a business development event, specifically a manufacturing agreement, which fits best under Capital/Financing Update (CAP) as it relates to strategic manufacturing and supply agreements impacting the company's operations and potentially its capital structure or business strategy. The document length is moderate and contains substantive content about the agreement, not just a brief notice or report publication announcement.
2021-04-26 English
Activities Report and App 4C for quarter ended 31 March 2021 10 pages 1.3MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Activities Report and Appendix 4C for March 2021 Quarter' and provides detailed financial and operational updates for the quarter ended 31 March 2021. It includes a quarterly cash flow statement (Appendix 4C), financial summary, progress on clinical trials, regulatory updates, commercial launch activities, sales data for the quarter, and payments to related parties. The content is comprehensive and covers a period shorter than a full fiscal year, with substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is IR (Interim / Quarterly Report). Q1 2021
2021-04-21 English
Japanese Renal Cancer Imaging Trial Meets Study Objectives 2 pages 209.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the results of a Phase I clinical study (ZIRDAC-JP) for a renal cancer imaging product by Telix Pharmaceuticals. It discusses study objectives, safety, tolerability, and pharmacokinetics, but does not contain financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or interim report. It is an update on clinical trial progress and study results, which is typical of a Capital/Financing Update or general company announcement. However, since it focuses on clinical trial results and not financing or capital structure changes, it does not fit CAP. It is not a regulatory filing or legal proceeding. The document is a company announcement about clinical trial progress and results, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2021-04-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.